A Retrospective Analysis Evaluating Allogeneic Cancellous Bone Sponge
The present retrospective case crossover study was conducted to determine the effectiveness and safety data associated with the use of an allogeneic, cancellous bone sponge in an orthopedic foot and ankle population. We reviewed the medical records of 47 subjects (80 joints) who had undergone foot and/or ankle fusion with the cancellous bone sponge. The records were reviewed up to 12 months postoperatively. The joints included in the present study were 12 ankles, 3 ankle syndesmotic fusions (with concurrent total ankle arthroplasty), 17 subtalar joints, 17 talonavicular joints, 9 calcaneocubiod joints, 1 naviculocuneiform joint, 13 first tarsometatarsal joints, 6 lesser tarsometatarsal joints, and 2 first metatarsophalangeal joints. The endpoints of the present studywere solid, sustained foot and ankle fusion, asdemonstrated radiographically, and the occurrence of unexpected adverse effects related to the graft. The fusion rates were compared with those reported in other studies. The patient-reported outcome variables for the present study included the visual analog pain scale and the American Orthopaedic Foot and Ankle Score. The use of a cancellous sponge showed statistically significant improvements in pain and function and comparable or better fusion rates compared with outcomes reported in other published reports.
Click the link to download the full article.
Authors:
Stephen A. Brigido, DPM, FACFAS, Scott T. Bleazey, DPM, AACFAS, Nicole M. Protzman, BS, MS, Albert D’Angelantonio III, DPM, AACFAS, Harold D. Schoenhaus, DPM, FACFAS
© 2013 by the American College of Foot and Ankle Surgeons. All rights reserved.
Recent News
- May 16th, 2013
The News on OsteoSponge SC - May 1st, 2013
Exploring The Potential Of Acellular Dermis Grafts For Wound Healing And Soft Tissue Repair - April 29th, 2013
A Retrospective Analysis Evaluating Allogeneic Cancellous Bone Sponge - April 1st, 2013
April is National Donate Life Month! - September 14th, 2012
Positive Clinical Results on the use of Bacterin’s OsteoSponge® SC Product - September 14th, 2012
Bacterin Secures $25 Million Financing with OrbiMed - May 7th, 2012
Facebook Partners with Donate Life to Increase Registered Organ Donors - April 4th, 2012
Peer Review Determines Bacterin’s OsteoSponge® Ideal for Bone Regeneration
